Qiagen NV's (QGen – free report) The first-quarter 2025 adjusted income per part (EPS) is 55 cents, and 56 cents at the ongoing exchange rate (CER). The bottom line rose 17% from last year's level. In addition, it exceeds the estimate of the Zacks consensus of 10%.
The adjustment does not include the impact of certain items that are not repeated, such as business integration, acquisition and costs related to repair, purchased unaware of amortization costs and cost-free costs, among others.
On a GAAP basis, the EPS in the first quarter is 41 cents compared to 36 cents last year.
Following the announcement, QGEN's stock rose 1.1% yesterday.
QGEN'S EVENING EVEN Q1
Net sales in the quarter was $ 483.5 million, up to 5.4% from last year (up to 7% in the cer). The top line defeated the Zacks Consensus estimate of 4.8%. (See Zacks revenue calendar to stay in advance of market making news.)
QGen's Q1 Revenue Breakdown
Qiagen reports through product groups, especially technology samples, diagnostic solutions, PCR / nucleic acid amplification, genomics / of and others.
Technologies of the example Revenues fall 3% on a reported basis (down 1% in CER) up to $ 150 million. Our model is expected to be $ 148 million for this segment.
Diagnostic solutions Revenues rise 9% on a reported basis (11% in CER) up to $ 187 million. Our model is expected to be $ 183.7 million for this segment.
In it, on a cer's basis, Quantiferon Revenues reach 16% and Qiastat-dx The revenues moved up by 37%. Sales from Neumodx fell 36% in cer, while Something else Sales dropped 9% from the year-level-more before.
PCR/nucleic acid amplification Revenues rise 13% on a reported basis (up to 14% in CER) up to $ 76 million. Our model is expected to be $ 66.6 million for this segment.
Genomics/NGS Revenues reached $ 53 million, down 3% year in the year on a reported basis and 2% on the CER. Our model is expected to be $ 55 million for this segment.
Something else Revenues cost $ 18 million, up to 57% years over year on a reported basis (up to 64% in the CER). Our model is expected to be $ 10.7 million for this segment.
Updating qiagen operation
In the first quarter, the cost of company sales (excluding the amortization of intangibles related to acquisition) fell 6.3%. The adjusted gross profit rose 4.9% years over the year to $ 322.2 million. Meanwhile, the fitting gross margin contracted 29 points (BPS) to 66.6%.
The sales and marketing costs fell 4.3% years over the year up to $ 106.3 million. R&D costs of $ 43.8 million dropped 14.7% year in the year. G&A costs rose 14.6% years over years to $ 31.6 million.
The adjective of the operating income (excluding items such as acquisition related to non -tangible amortization, repair, integration, integration and so on) increased by 20% year in the year to $ 140.4 million. The adjective operating margin expanded 354 bps up to 29%.
Updating Qgen's Finance
Qiagen appeared in the first quarter of 2025 with cash, equivalent to cash and short-term investments of $ 963.4 million compared to $ 1.20 billion at the end of the fourth quarter of 2024.
Qiagen NV price, EPS agreed and surprise
The long-term debt (net of the current part) is $ 1.35 billion at the end of the first quarter of 2025 compared to $ 1.34 billion at the end of the fourth quarter of 2024.
The net cash provided by operating activities at the end of the first quarter of 2025 was $ 139.7 million compared to $ 133.1 million during last year.
Qiagen Reaffirms Outlook for 2025, sets a Q2 view
For 2025, net sales are expected to increase about 4% cer (about +5% cer core sales growth). The estimate of the agreed Zacks for revenues is up to $ 2.02 billion.
The adjusted EPS is expected to be $ 2.35 in the CER (ascending from a previous $ 2.28 perspective on the CER). The estimate of the agreed Zacks is up to $ 2.27.
For the second quarter, the company estimates Net Sales to rise nearly 5% on the CER (about 5% in CER in the main business) from $ 496 million last year. The estimate of the agreed Zacks is currently on $ 505.9 million.
The adjusted EPS is expected to be at least 60 cents in the cer compared to 55 cents in the second quarter of 2024. The estimate of the Zacks's approach is located at 56 cents.
Our taking in QGen
Qiagen ended the first quarter of 2025 with better results, where both income and income exceeded their estimates. The company's performance reflects an elastic portfolio, with a large portion of sales that come from quite repeated revenue and an ongoing emphasis on delivering strong income to a challenging environment.
Diagnostic solutions are registered with maximum growth, driven by strong demand for quantiferon and qiastat-DX. PCR/nucleic acid amplification technologies also post solid growth, supported by the continued adoption of the qiacuity digital PCR system. Consumables and relevant revenues have grown as instrument sales are flat in the year, reflecting ongoing careful capital expenditure trends with customers. In addition, expanding the operating margin in the quarter is encouraging.
Qiagen remains focused on delivering its 2025 view, which puts a way to achieve its 2028 goal. However, increasing costs and declines of gross margins are not fixed.
The rank of QGen's Zacks and other major picks
Qiagen is currently carrying a rank of Zacks #2 (buy).
Other top stock rankings from the wider medical space is AngiodynamiCS (ANGO – free report), Integer Holdings Corporation (ITGR – free report) and Boston Scientific (BSX – Free report).
Angiodynamics, currently playing a rank of Zacks #1 (strong purchase), reports a third-quarter fiscal 2025-adjusted EPS 3 cent against the Zacks Consensus estimate of a 13-cent loss. Earnings of $ 72 million defeated the estimate of the agreed Zacks of 2%. You can see the complete list of Zacks #1 stock rankings today.
The ANGO has an estimated fiscal 2026 income growth rate of 27.8% compared to the growth of 10.5% S&P 500 growth. The company exceeds revenue estimates in each of the trailing four quarter, the average surprise is 70.9%.
Integer holders, walking a rank of Zacks #1 at present, posted a first-quarter 2025 suits of $ 1.31, which exceeded the Zacks Consensus estimate of 3.1%. Revenues of $ 437.4 million exceed the Zacks Consensus estimate of 1.3%.
ITGR has an estimated long -term income growth rate of 20.8% compared to 14.3% of the industry. The company's revenues exceed estimates to three of the trailing four quarters and have not been acquired on one occasion, the average surprise is 2.8%.
The Boston Scientific, which currently carries a Zacks Rank #2 (Buy), reports a first-quarter 2025-adjusted EPS of 75 cents, which exceeds the Zacks Consensus estimate of 11.9%. Earnings of $ 4.66 billion led the Zacks Consensus estimate of 2.3%.
BSX has an estimated 2025 income growth rate of 15.9% compared to 11.9% growth of the S&P 500 composite. The company's revenues exceed estimates to each other in the trailing four quarters, delivering an average surprise of 8.8%.
Seven best stocks for the next 30 days
Released only: Disill disill 7 Elite Stocks from the current list of 220 Zacks Rank #1 Strong Purchase. They think these tickers are “probably for early pop prices.”
Since 1988, the entire list has beaten the market more than 2x over with an average gain of +23.9% per year. So be sure to give these hands taken 7 your immediate attention.
Do you want the latest recommendations from Zacks Investment Research? Download 7 best stocks for the next 30 days. Click to get this free report
